Association between P-Selectin Autoantibody Positive and Response to Steroid Treatment in Newly Diagnosed Immune Thrombocytopenia Patients

Abstract

<b><i>Objective:</i></b> This study aimed to detect the association between P-selectin autoantibody positive and response to steroid treatment in newly diagnosed immune thrombocytopenia (ITP) patients. <b><i>Methods:</i></b> The data from 105 newly diagnosed adult ITP patients administered with first-line of steroid treatment from October 2016 to May 2021 were retrospectively analyzed. Treatment responses were evaluated within 3 months after the onset of treatment. <b><i>Results:</i></b> Among the 105 patients, 80.00% (84/105) of patients presented with platelet glycoprotein-specific antibody positive; 44.76% (47/105) patients were anti-P-selectin positive, while 35.24% (37/105) were anti-P-selectin negative. No significant difference in overall response was observed between patients who were anti-P-selectin positive and those who were anti-P-selectin negative (74.47% vs. 89.19, χ² = 2.910, <i>p</i> = 0.088). But patients who were anti-P-selectin negative had significantly higher complete response rate, compared to those who were anti-P-selectin positive (72.97% vs. 48.94%, χ² = 4,965, <i>p</i> = 0.026). Logistic regression analysis revealed that anti-GP IIb/IIIa positive (OR = 3.114, <i>p</i> = 0.010, 95% CI: 1.313–7.388) and anti-P-selectin positive (OR = 0.309, <i>p</i> = 0.036, 95% CI: 0.127–0.753) were two factors that could affect patients’ response. <b><i>Conclusions:</i></b> Our study found that ITP patients with anti-GP IIb/IIIa may have a higher response to steroid treatment, but anti-P-selectin-mediated-ITP might be less responsive to steroid treatment. In adults with ITP, the presence of anti-P-selectin autoantibodies is a predictive factor for poor response to steroid treatment.